 |
|
| NOVEL ANTICANCER AGENTS
| |
| | |
|
|
Strategies for Discovery and Clinical Testing
To order this title, and for more information, click here
Edited By
Alex Adjei, Mayo Clinic, Rochester, Minnesota, U.S.A.
John Buolamwini, University of Tennessee Health Science Center, Memphis, Tennessee, U.S.A.
Description
This book offers pertinent basic science information on strategies used for the rational design and discovery of novel anticancer agents,
and, in addition, translational studies involving clinical trial design and execution with these novel, mostly cytostatic agents. This
book covers basic science strategies that are being used in drug discovery and preclinical evaluation focused on novel molecular targets,
as well as clinical trial methodology including clinical pharmacokinetics and imaging to address issues of efficacy evaluation of the
new, relatively non-cytotoxic anticancer agents.
At present, there is no book that provides such an integration of basic and clinical
studies of novel anticancer agents, covering both drug discovery and translational research extensively.
Audience
Researchers in pharmacology and oncology (both government and industry), clinical oncologists who are in clinical research in universities
or in industry, anticancer drug discovery and development scientists, research libraries, postgraduate students, fellows and general
oncology practicing physicians.
Contents
Section A: Strategies for Drug Discovery.
1. A Survey of Novel Molecular Targets for Anticancer Drug Discovery.
2. Microarrays: Small
Spots Produce Major Advances in Pharmacogenomics.
3. Strategies to Target Chemotherapeutics to Tumors.
4. QSAR and Pharmacophore Mapping
Strategies in Novel Anticancer Drug Discovery.
5. Applications of Nuclear Magnetic Resonance and Mass Spectrometry to Anticancer Drug
Discovery.
6. Antisense Strategies for the Development of Novel Cancer Therapeutics.
7. Antibodies and Vaccines as Novel Cancer Therapeutics.
8. Inhibitors of Apoptosis (IAPs) as Targets for Cancer Therapy.
9. Preclinical Testing and Validation of Novel Anticancer Agents.
Section
B: Methods for Clinical Testing of Novel Agents.
10. Biologic Endpoints and Surrogate Markers for Ealry Trials of Novel Anticancer Agents.
11. Regulatory Considerations in Clinical Trials of Novel Anticancer Drugs.
12. Improving the Efficacy and Safety of Anticancer Agents
- The Role of Pharmacogenetics.
13. Imaging of Pharmacodynamic Endpoints in Clinical Trials.
14. Devising Proof of Concept Strategies
in Oncology Clinical Trials.
15. Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets.
16 Cancer
Gene Therapy Clinical Trials: From the Bench to the Clinic.
17. Molecular Targest for Radiosensitization.
18. Patient Accrual to Clinical
Trials.
| Bibliographic details |
Hardbound, 464 pages, publication date: DEC-2005
ISBN-13: 978-0-12-088561-9
ISBN-10: 0-12-088561-1
Imprint: ACADEMIC PRESS
|
| Price and Ordering |
Price:
GBP 102
USD 160
EUR 119.95
|  |
Books and book related electronic products are priced in US dollars (USD), euro (EUR), and Great Britain Pounds (GBP). USD prices apply to the Americas and Asia Pacific. EUR prices apply in Europe and the Middle East. GBP prices apply to the UK and all other countries.
|
See also information about conditions of sale & ordering procedures, and links to our regional sales offices.
|
092/900
Last update: 5 Sep 2009
|
|
| |
| | |
|
|
| |
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company